| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7265221 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| US7301023 | PF PRISM CV | Chiral salt resolution |
Dec, 2020
(3 years ago) | |
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(1 year, 1 month ago) | |
| USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7842699 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| US7091208 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
| US6956041 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(3 years ago) | |
Xeljanz is owned by Pf Prism Cv.
Xeljanz contains Tofacitinib Citrate.
Xeljanz has a total of 7 drug patents out of which 6 drug patents have expired.
Expired drug patents of Xeljanz are:
- US7842699
- US7091208
- US6956041
- US7265221
- US7301023
- US6965027
Xeljanz was authorised for market use on 06 November, 2012.
Xeljanz is available in tablet;oral dosage forms.
Xeljanz can be used as treatment of adult patients with moderately to severely active ulcerative colitis (uc), treatment of rheumatoid arthritis.
Drug patent challenges can be filed against Xeljanz from 06 November, 2016.
The generics of Xeljanz are possible to be released after 08 December, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-879) | Dec 14, 2024 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-761) | Dec 14, 2020 |
| M(M-135) | Feb 21, 2017 |
| New Indication(I-780) | May 30, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 06 November, 2016
Market Authorisation Date: 06 November, 2012
Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis
Dosage: TABLET;ORAL
XELJANZ family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(1 year, 7 months from now) | |
Xeljanz is owned by Pfizer.
Xeljanz contains Tofacitinib Citrate.
Xeljanz has a total of 1 drug patent out of which 0 drug patents have expired.
Xeljanz was authorised for market use on 25 September, 2020.
Xeljanz is available in solution;oral dosage forms.
The generics of Xeljanz are possible to be released after 08 December, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 25, 2023 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 25 September, 2020
Treatment: NA
Dosage: SOLUTION;ORAL
XELJANZ family patents